China Biotech Weekly #11: Q1 2026 Deal Pace — Average Values 76% Larger Than 2025

This Week's Top Takeaway

Average China-to-West deal sizes in Q1 2026 are tracking 76% larger than 2025, with average values reaching approximately $1.3 billion per transaction. The mega-deal phenomenon that defined 2025 is accelerating, not normalizing. Three structural factors are driving this: (1) Chinese pipeline maturity reaching Phase II/III across multiple modalities, (2) Big Pharma LOE anxiety creating urgency to license external assets, and (3) the CDE speed premium being priced into deal terms as a quantifiable value driver.

BIOSECURE Watch: 9 Months to BCC List

Status: 🟡 Ongoing Review

The OMB BCC list deadline is December 2026 — 9 months away. Key developments:

OMB activity: No public rulemaking or guidance yet. Internal interagency consultations are reportedly underway, but the process remains opaque. Industry associations have requested (and not received) a public comment period.
Pentagon 1260H: No new list update since the withdrawn February 13 filing. WuXi AppTec remains not listed.
SEC disclosures: Approximately 14 public companies have now added BIOSECURE risk factors. The pace has slowed as most exposed companies have already disclosed.
WuXi restructuring: WuXi AppTec Q4 2025 earnings showed continued revenue growth from US clients. WuXi XDC IPO timeline reportedly pushed to H2 2026.

The 9-month calculation matters because: CDMO tech transfers take 18-24 months. If your programs depend on a potentially designated entity, you are already inside the window where a BCC designation could delay your clinical timeline. The math doesn't work if you wait for the list.

CDE Filing Watch

Zai Lab (再鼎医药) filed regulatory submissions for two pipeline candidates — one in-licensed from a Western partner and one internally developed. Zai Lab's bi-directional model continues to generate CDE activity in both directions.

CSPC Pharmaceutical (石药集团) received CDE approval for a manufacturing expansion at its small molecule API facility. This is consistent with CSPC's scale-up ahead of the AstraZeneca partnership's clinical development needs.

Preview: Spring Conference Season

Three conferences in the next 6 weeks will generate significant China deal flow intelligence:

BIO CEO & Investor Conference (March) — Expect at least 2-3 China-originated licensing announcements
AACR Annual Meeting (April) — Chinese ADC and bispecific clinical data will dominate poster sessions
ASCO Annual Meeting (June) — Nearly one-third of presentations in 2025 involved Chinese company drug candidates; expect even higher representation in 2026

BD teams should have active scouting mandates at all three events, with specific attention to Chinese companies presenting Phase II oncology data — this is the asset maturity sweet spot for out-licensing.

Takeaways for BD Teams

The 76% average deal size increase is not a bubble — it reflects asset maturity. Chinese pipelines are reaching later stages with better data, commanding higher valuations. The comp set is shifting from "China discount" to "China premium" for differentiated mechanisms.

Watch the NewCo model. If your BD strategy assumes traditional licensing structures, you may be competing against equity-backed NewCos that offer Chinese licensors better economics. Understand this emerging competitor structure.

The BIOSECURE 9-month countdown is real. Tech transfer timelines exceed the remaining window. If you're still in "monitoring" mode on WuXi exposure, you're behind.

AACR and ASCO are your scouting events. Chinese companies presenting Phase II data at these conferences are the assets that will be licensed in Q3-Q4 2026. Be there.

China Biotech Weekly is published every Thursday. For questions, tips, or deal intelligence, reach out at antony@chinabiointel.com. — Antony Tan